Key value drivers

Potential near-and mid-term value drivers

• Sustained M&A & in-licensing to build critical mass in oncology
• Cantrixil – initiation of Phase 2
• Docetaxel micellar – Phase 1b completion
• Apealea® – initiation of additional US pivotal studies by Elevar; partnering in key territories; potential for initial royalties
• XR-17™ technology platform – enhancement
• Animal Health assets – divestment or partnering agreements

• 2 nd most common

  Cancer is the 2nd most common cause of death¹

• 18 million people

  18 million people were diagnosed with cancer in 2018¹

• USD 240 billion

  The total expenditure on oncology worldwide in 2023 is estimated to be USD 240 billion²

¹ World Cancer Research Fund
² Global Oncology Trends 2019 – Therapeutics, Clinical Development and Health System Implications. IQVIA Institute for Human Data Science.